U.S. CDC Advisory Committee Unanimously Recommends Routine Use of Beyfortus (nirsevimab-alip) to Protect Infants Against RSV Disease
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
Committee also voted unanimously to include Beyfortus in the Vaccines for Children program,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Initial Patients Enrolled in Groundbreaking Tardive Dyskinesia Detection Study
CLEVELAND, Aug. 2, 2023. iRxReminder, LLC, a pioneer in medical adherence technology, is thrilled to announce the enrollment of its first patients in the innovative NIMH-funded study, the TDtect™ Diagnostic. The study leverages... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Placebo-Controlled, Phase 1 Study to Investigate the Effect of Obicetrapib on Lipoprotein Metabolism
Conditions: Hyperlipidemias; Dyslipidemias Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Conditions: Hyperlipidemias; Dyslipidemias Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Conditions: Hyperlipidemias; Dyslipidemias Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Conditions: Hyperlipidemias; Dyslipidemias Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Conditions: Hyperlipidemias; Dyslipidemias Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Condition: Left Ventricular Thrombus Interventions: Drug: Warfarin; Drug: Rivaroxaban 20 MG Oral Tablet; Drug: Apixaban 5mg or 2.5mg oral tablet Sponsors: Peshawar Institute of Cardiology; Getz Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
